The Endothelial Supplement Stack: A New Meta-Analysis Ranks What Actually Moves FMD

The paper, published in Current Atherosclerosis Reports in 2026, pools randomized trials of dietary interventions and uses a network meta-analysis to compare them indirectly when no head-to-head trial exists. The output is a ranked list with two numbers attached to each supplement: a mean difference in FMD (in percentage points), and a GRADE certainty-of-evidence rating that tells you how much to trust the estimate. Read together, they sort signal from noise in a category where noise is the default.

Two compounds top the table with the strongest certainty grade the authors give out. Magnesium produced a mean difference of 8.17 percentage points in FMD, with high certainty of evidence; vitamin D3 came in just behind at 7.84 points, also rated high certainty. For context, those are not subtle shifts — they are the kind of magnitude usually associated with lifestyle interventions like aerobic training programs, not a capsule.

Below the two leaders, the certainty grades start to fray. Flaxseed posted a mean difference of 7.39 points, but on low-certainty evidence; barberry came in at 6.64 points with moderate certainty; folic acid added 3.36 points on low-certainty evidence; and omega-3 — the supplement most readers probably already own — managed only a 1.83-point bump, rated very low certainty. The authors note that sensitivity analyses did not unravel the top of the ranking, which is reassuring for the magnesium and D3 signals in particular.

The shape of that list matters more than any single number. The strongest effects belong to two cheap, well-characterized micronutrients with plausible mechanistic stories — magnesium as a cofactor in vascular smooth-muscle relaxation and nitric oxide signaling, vitamin D3 as a regulator of endothelial and renin-angiotensin pathways. Several flashier options — including the omega-3 that anchors most cardiovascular supplement aisles — sit lower on the list with weaker evidence behind them.

A network meta-analysis is a useful synthesis tool, not a verdict. It chains together trials that often used different doses, durations, baseline populations, and FMD measurement protocols, then estimates indirect comparisons through a statistical web. The GRADE certainty rating is the field's attempt to flag how much of that machinery is load-bearing on shaky inputs. When a result earns a high rating — as magnesium and vitamin D3 did here — it means the underlying trials were consistent, reasonably sized, and at low risk of bias. When the rating slides to low or very low, the headline number is more of a hypothesis than a finding.

There are a few specific cautions worth carrying into the next conversation about supplements. The trials feeding this analysis were conducted in people with cardiovascular disease or hypertension — populations whose endothelial function has more room to improve than a healthy thirty-year-old's. Extrapolating an 8-point FMD bump to a recreational athlete with normal blood pressure is exactly the kind of leap the data does not support. And FMD is a surrogate marker: a real-time readout of vascular behavior, strongly correlated with cardiovascular outcomes in observational work, but not the same thing as a reduction in heart attacks or strokes proven in a trial.

None of that erases the practical signal. It just clarifies what the signal is. The authors frame their results as a basis for designing future trials and developing evidence-based nutritional guidelines, positioning these compounds as potential adjunct therapies for preserving vascular health — not as replacements for the things that actually lower events, like blood pressure control, statins where indicated, exercise, and sleep.

For an endurance athlete already eating well, the takeaway is less about adding bottles and more about checking the basics. Magnesium and vitamin D status are both routinely under-replete in heavy trainers, and both showed up at the top of an endothelial-function ranking on the strongest evidence grade in this analysis. Whether correcting a deficiency in an otherwise healthy person produces FMD improvements anywhere near the magnitudes seen in patient populations is, candidly, not what the trials were designed to answer.

The honest read of this meta-analysis is narrow but useful. If you already have a cardiovascular or hypertensive diagnosis, the data suggest magnesium and vitamin D3 are reasonable adjunct conversations to have with a clinician, with the strongest evidence behind them of the supplements tested. Several other options on the list remain plausible but underpowered. Omega-3, despite its cultural status, did not perform impressively on this particular endpoint with this particular evidence base. None of that is a prescription — it is a sharper map of what the literature currently supports.